About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Hepatobiliary Tumors Tissue Samples Acquisition | Clinical Trials | Clareo Health

Back to clinical trial search

UNKNOWNNCT04445532

Hepatobiliary Tumors Tissue Samples Acquisition

Hepatobiliary tumors have a poor prognosis and high individual heterogeneity, so it is of great significance to find important prognostic markers and then screen out specific subgroups of people; mean...

Lead sponsor: Peking Union Medical College Hospital•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

XiaoBo Yang, MD

CONTACT

+86-138-1167-5126 yangxiaobo67@pumch.cn

Haitao Zhao, MD

CONTACT

zhaoht@pumch.cn

Sponsors

Lead Sponsor

Peking Union Medical College Hospital

Collaborators

OrigiMed
GeneCast Biotechnology Co., Ltd.
YuceBio Technology Co., Ltd.
Geneplus-Beijing Co. Ltd.

OBJECTIVES: 1. Observe the biomarkers of resectable hepatobiliary tumor recurrence (DFS) and survival (OS); 2. Observe the evolution of tumors and discover specific diagnostic markers as a control group. 3. Observe the response (ORR), progression (PFS) and survival (OS) biomarkers of targeted immunotherapy for advanced hepatobiliary tumors; 4. To elaborate on the multi-omics study of hepatobiliary tumors, to further subtype and find therapeutic targets

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Be older than 18 years old;
•2. ECOG 0-2 points;
•3. May have received treatment;
•4. Clinical consideration or diagnosis of benign and malignant hepatobiliary tumors; or chronic hepatitis, cirrhosis, or healthy control participants;
•5. Patients may have received or are about to undergo surgery, chemotherapy, radiotherapy, targeted therapy, local therapy, immunotherapy, etc.;
•6. Patients understand and are willing to sign written informed consent documents.

Exclusion Criteria

•1. The doctor thinks it is not suitable to enter the group (mental disorder or poor compliance, etc.)
•2. Pregnant women;
•3. Active or uncontrollable infections (fungi, bacteria, etc.);
•4. Estimated survival time \<12 weeks;
•5. If the patient is receiving chronic anticoagulant therapy, the anticoagulant withdrawal should not be shorter than 3 days;
•6. In the evaluation of the doctor, there is a risk of uncontrolled complications in the biopsy.

Related studies

MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.

NCT07607769 · Hepatocellular Carcinoma

RECRUITINGPhase 1

A Study of PHST001 in Advanced Solid Tumors

NCT06840886 · Advanced Solid Tumors, Ovarian Cancer, and more

RECRUITINGPhase 2/3

Trop2-targeted immunoPET Imaging of Solid Tumors

NCT06851663 · Solid Tumor, Solid Carcinoma, and more

Efficacy and Safety of SIRT-Y90 in Combination With Atezo + Bev for Unresectable Hepatocellular Carcinoma

NCT07610551 · HCC - Hepatocellular Carcinoma

Endobiliary Radiofrequency Ablation for Malignant Biliary Obstruction Due to Perihilar Cholangiocarcinoma

NCT05546372 · Perihilar Cholangiocarcinoma

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 7, 2023Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment450

Start dateOct 2020

Last updatedJul 7, 2023

Condition

Hepatocellular Carcinoma Cholangiocarcinoma Gallbladder Cancer Biliary Tract Cancer Liver Cancer+3 more

Locations shown

Chinese Academy of Medical Sciences & Peking Union Medical College Hospital

Beijing, Beijing Municipality

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 7, 2023Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions